Prostate Cancer and the Mevalonate Pathway

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 24

PMID 38396837

Authors

Patricia Guerrero-Ochoa

Sergio Rodriguez-Zapater

Alberto Anel

Luis Mariano Esteban

Alejandro Camon-Fernandez

Raquel Espilez-Ortiz

Maria Jesus Gil-Sanz

Angel Borque-Fernando

Affiliations

Soon will be listed here.

Abstract

Antineoplastic therapies for prostate cancer (PCa) have traditionally centered around the androgen receptor (AR) pathway, which has demonstrated a significant role in oncogenesis. Nevertheless, it is becoming progressively apparent that therapeutic strategies must diversify their focus due to the emergence of resistance mechanisms that the tumor employs when subjected to monomolecular treatments. This review illustrates how the dysregulation of the lipid metabolic pathway constitutes a survival strategy adopted by tumors to evade eradication efforts. Integrating this aspect into oncological management could prove valuable in combating PCa.

Citing Articles

A pharmacoinformatic approach for studying DC's anticancer potential and control ROS-mediated apoptosis against prostate cancer cells.

Ahn C, Myong J, Ahmed K, Rahman M, Maharub Hossain Fahim M, Choi M Front Oncol. 2025; 15:1471110.

PMID: 39980567 PMC: 11841406. DOI: 10.3389/fonc.2025.1471110.

Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling.

Iannelli F, Lombardi R, Costantini S, Roca M, Addi L, Bruzzese F Cancer Cell Int. 2024; 24(1):381.

PMID: 39550583 PMC: 11569608. DOI: 10.1186/s12935-024-03573-1.

Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer.

Uzelac M, Xin R, Ongkeko W Int J Mol Sci. 2024; 25(6).

PMID: 38542265 PMC: 10970102. DOI: 10.3390/ijms25063291.

References

Jayalath V, Lajkosz K, Fleshner N, Hamilton R, Jenkins D . The effect of lowering cholesterol through diet on serum prostate-specific antigen levels: A secondary analysis of clinical trials. Can Urol Assoc J. 2022; 16(8):279-282. PMC: 9343158. DOI: 10.5489/cuaj.7975. View

Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J . Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med. 2009; 14(5):1180-93. PMC: 3822754. DOI: 10.1111/j.1582-4934.2009.00771.x. View

Dickerman B, Garcia-Albeniz X, Logan R, Denaxas S, Hernan M . Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019; 25(10):1601-1606. PMC: 7076561. DOI: 10.1038/s41591-019-0597-x. View

Boon R, Silveira G, Mostoslavsky R . Nuclear metabolism and the regulation of the epigenome. Nat Metab. 2020; 2(11):1190-1203. DOI: 10.1038/s42255-020-00285-4. View

Zaleski A, Taylor B, Thompson P . Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but…. Adv Nutr. 2018; 9(4):519S-523S. PMC: 6054172. DOI: 10.1093/advances/nmy010. View

Maxfield F, van Meer G . Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol. 2010; 22(4):422-9. PMC: 2910236. DOI: 10.1016/j.ceb.2010.05.004. View

Kim S, Richardson M, Chinnakannu K, Bai V, Menon M, Barrack E . Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 2010; 285(14):10472-6. PMC: 2856254. DOI: 10.1074/jbc.M109.098798. View

Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M . Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 2005; 314(3):1032-41. DOI: 10.1124/jpet.105.086462. View

Mullen P, Yu R, Longo J, Archer M, Penn L . The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016; 16(11):718-731. DOI: 10.1038/nrc.2016.76. View

10.

Chiarugi A, Dolle C, Felici R, Ziegler M . The NAD metabolome--a key determinant of cancer cell biology. Nat Rev Cancer. 2012; 12(11):741-52. DOI: 10.1038/nrc3340. View

11.

Wang K, Gerke T, Chen X, Prosperi M . Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. Cancer Med. 2019; 8(17):7399-7407. PMC: 6885894. DOI: 10.1002/cam4.2500. View

12.

Sivanand S, Viney I, Wellen K . Spatiotemporal Control of Acetyl-CoA Metabolism in Chromatin Regulation. Trends Biochem Sci. 2017; 43(1):61-74. PMC: 5741483. DOI: 10.1016/j.tibs.2017.11.004. View

13.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M . Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet. 2018; 50(2):219-228. PMC: 5810912. DOI: 10.1038/s41588-017-0026-3. View

14.

Athanassiadou P, Bantis A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E . Telomerase expression as a marker in prostate cancer: correlation to clinicopathologic predictors. J Exp Clin Cancer Res. 2004; 22(4):613-8. View

15.

Guertin D, Wellen K . Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023; 23(3):156-172. PMC: 11137663. DOI: 10.1038/s41568-022-00543-5. View

16.

Dorsch M, Kowalczyk M, Planque M, Heilmann G, Urban S, Dujardin P . Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Rep. 2021; 37(8):110056. PMC: 8640221. DOI: 10.1016/j.celrep.2021.110056. View

17.

Mollinedo F, Gajate C . Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts. J Lipid Res. 2021; 61(5):611-635. PMC: 7193951. DOI: 10.1194/jlr.TR119000439. View

18.

Grolez G, Gordiendko D, Clarisse M, Hammadi M, Desruelles E, Fromont G . TRPM8-androgen receptor association within lipid rafts promotes prostate cancer cell migration. Cell Death Dis. 2019; 10(9):652. PMC: 6733924. DOI: 10.1038/s41419-019-1891-8. View

19.

Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D . Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. Front Oncol. 2020; 10:1510. PMC: 7472741. DOI: 10.3389/fonc.2020.01510. View

20.

Gasinska A, Jaszczynski J, Rychlik U, Luczynska E, Pogodzinski M, Palaczynski M . Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy. Pathol Oncol Res. 2019; 26(2):1049-1056. PMC: 7242245. DOI: 10.1007/s12253-019-00659-4. View